Medoril

Calcium Dobesilate, the active ingredient in Medoril, is a vasoprotective agent presented as an oral dosage form for oral use. It is employed to manage chronic venous insufficiency, hemorrhoidal disease, diabetic retinopathy and capillary fragility.

GNH USA supplies Medoril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medoril is a vasoprotective drug used to treat disorders of the microcirculation and venous system.

- Chronic venous insufficiency: reduces edema and improves venous return. - Hemorrhoidal disease: lessens bleeding and discomfort. - Diabetic retinopathy: stabilises retinal microvascular leakage. - Capillary fragility: strengthens capillary walls and limits bruising.

Adverse reactions may occur with any vasoprotective therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient tension‑type headache. - Dizziness: occasional light‑headedness. - Skin rash: mild erythematous eruption.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema. - Hepatic dysfunction: elevated transaminases. - Hematologic abnormalities: thrombocytopenia or neutropenia.

Use Medoril with attention to patient‑specific risk factors.

- Renal impairment: monitor renal function and adjust therapy if needed. - Pregnancy: prescribe only when benefits outweigh potential risks. - Elderly patients: observe for increased dizziness or hypotension. - Concomitant anticoagulants: assess bleeding risk regularly. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Calcium Dobesilate may alter the effect of certain co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding tendency. - High‑dose NSAIDs: heightened risk of gastrointestinal irritation.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive blood‑pressure lowering. - Diuretics: monitor electrolyte balance. - Other vasoprotective agents: assess for overlapping side‑effects.